Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ

Advisors Preferred LLC bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,861 shares of the specialty pharmaceutical company's stock, valued at approximately $5,079,000.

Other large investors have also recently made changes to their positions in the company. Cardinal Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company's stock worth $2,471,000 after purchasing an additional 66 shares during the period. Bessemer Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 0.3% in the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock worth $4,228,000 after acquiring an additional 73 shares during the period. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company's stock valued at $123,000 after buying an additional 81 shares in the last quarter. Pinnacle Associates Ltd. grew its stake in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company's stock valued at $1,905,000 after acquiring an additional 83 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.4% in the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company's stock worth $377,000 after purchasing an additional 85 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Down 1.4%

NASDAQ:JAZZ opened at $248.70 on Friday. The company has a market cap of $16.15 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. Jazz Pharmaceuticals PLC has a twelve month low of $118.19 and a twelve month high of $265.05. The stock has a fifty day simple moving average of $244.31 and a 200-day simple moving average of $215.02. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company's quarterly revenue was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($8.25) EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post 21.66 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company's stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Douglas Smith sold 1,157 shares of the firm's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares in the company, valued at approximately $2,231,724. This represents a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 14,357 shares of company stock worth $3,505,642. Company insiders own 4.10% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on JAZZ. TD Cowen increased their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. UBS Group restated a "buy" rating and issued a $315.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. Sanford C. Bernstein restated a "market perform" rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Raymond James Financial reaffirmed an "outperform" rating and issued a $239.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada lifted their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $272.89.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source